Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced that an updated overall survival analysis of the Phase 3 NAPOLI-1 study of ONIVYDE® (irinotecan liposome injection) in combination …
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced that an additional overall survival analysis from the Phase 3 NAPOLI-1 study of ONIVYDE™ (irinotecan liposome injection), also known …
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) and Baxalta Incorporated (NYSE:BXLT) jointly announced that The Lancet has published the article “Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic …
Merrimack Pharmaceuticals Inc (NASDAQ:MACK), a biopharmaceutical company that applies systems biology to develop cancer treatments and diagnostics, today announced its third quarter 2015 financial …
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) and Baxalta Incorporated (NYSE:BXLT) jointly announced the enrollment of the first patient in an exploratory Phase 2 clinical study of …
Analysts weigh in on the biopharmaceutical company Merrimack Pharmaceuticals Inc (NASDAQ:MACK) and biotechnology company Cytokinetics, Inc. (NASDAQ:CYTK), with positive ratings and views.
Merrimack Pharmaceuticals Inc (NASDAQ:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer, …
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced that Yasir Al-Wakeel, MA, BM BCh will be appointed Chief Financial Officer and head of Corporate Development on August …
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares jumped over 9% in pre market trading to $12.98 after its New Drug Application for MM-398 was accepted for …
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) and Baxalta Incorporated, a wholly-owned subsidiary of Baxter International Inc (NYSE: BAX), today jointly announced that the New Drug …
